drugset / Trial / NCT03706365

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

NCT03706365

Phase 2/3 Active not recruiting 393 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

Timeline

Start
2018-11-26
Primary completion
2024-01-02
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 150 mg Oral
Subject Abemaciclib Small molecule 200 mg Oral
Background Abiraterone acetate Small molecule 1000 mg Oral
Background Prednisone Other / unclassified 5 mg Oral

Indications